Skip to main content
SpringerLink
Log in

Drug Resistance in Leukemia and Lymphoma III

  • Book
  • © 1999

Overview

Editors:
  1. G. J. L. Kaspers

    1. University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. R. Pieters

    1. University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. A. J. P. Veerman

    1. University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 457)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (69 chapters)

  1. Front Matter

    Pages i-xiv
    Download chapter PDF

  2. Drug Resistance Related Proteins and Glutathione

    1. MDR1/P-GP Expression as A Prognostic Factor in Acute Leukemias

      • Jean-Pierre Marie, Ollivier Legrand
      Pages 1-9

    2. Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute Lymphoblastic Leukemia

      • Catharina Dhooge, Barbara De Moerloose
      Pages 11-19

    3. Prognostic Value of P-gp Expression and Related Function in Childhood Acute Leukemia

      • Z. KarakaÅŸ, L. AÄŸaoÄŸlu, S. Erdem, G. Yanikkaya Demirel, M. Arasa, F. Süzergöz et al.
      Pages 21-28

    4. Comparison of P-Glycoprotein Expression and Function with in vitro Sensitivity to Anthracyclines in AML

      • Alena W. Elgie, Jean M. Sargent, Christine J. Williamson, Grazyna M. Lewandowicz, Colin G. Taylor
      Pages 29-33

    5. Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP)

      • E. Wattel, E. Solary, B. Hecquet, D. Caillot, N. Ifrah, A. Brion et al.
      Pages 35-46

    6. Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) Plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC)

      • R. Advani, G. Visani, D. Milligan, H. Saba, M. Tallman, J. M. Rowe et al.
      Pages 47-56

    7. Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow Cytometry Using Two Different Monoclonal Antibodies Coupled with Functional Efflux Analysis in 34 Patients with Acute Myeloid Leukemia

      • S. Poulain, P. Lepelley, N. Cambier, A. Cosson, P. Fenaux, E. Wattel
      Pages 57-63

    8. Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-Cell Leukaemias

      • Annemarie Larkin, Elizabeth Moran, Denis Alexander, Martin Clynes
      Pages 65-70

    9. A Mutation in the Promoter of the Multidrug Resistance Gene (MDR1) in Human Hematological Malignancies may Contribute to the Pathogenesis of Resistant Disease

      • Deborah Rund, Idit Azar, Olga Shperling
      Pages 71-75

    10. Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blasts

      • M. Pallis, J. Turzanski, S. Langabeer, N. H. Russell
      Pages 77-88

    11. Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclines

      • M. Monici, F. Fusi, P. Mazzinghi, A. Degli Innocenti o Nocentini, I. Landini, I. Banchelli et al.
      Pages 89-94

    12. Artificial Neural Networks as Versatile Tools for Prediction of MDR-Modulatory Activity

      • C. Tmej, P. Chiba, K.-J. Schaper, G. Ecker, W. Fleischhacker
      Pages 95-105

    13. Discordance of P-Glycoprotein Expression and Function in Acute Leukemia

      • Barbara De Moerloose, Catharina Dhooge, Jan Philippé
      Pages 107-118

    14. Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas

      • Christian W. van Haselen, Marcel J. Flens, Rik J. Scheper, Paul van der Valk, George L. Scheffer, Johan Toonstra et al.
      Pages 119-131

    15. The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemia

      • Robert Pirker, Gudrun Pohl, Thomas Stranzl, Ralf W. Suchomel, Rik J. Scheper, Ulrich Jäger et al.
      Pages 133-139

    16. MRP Expression in Acute Myeloid Leukemia

      • Martin Filipits, Thomas Stranzl, Gudrun Pohl, Ralf W. Suchomel, Sabine Zöchbauer, Raoul Brunner et al.
      Pages 141-150

    17. Evidence for Functional Discrimination Between Leukemic Cells Overexpressing Multidrug-Resistance Associated Protein and P-Glycoprotein

      • Zineb Benderra, Hamid Morjani, Aurélie Trussardi, Michel Manfait
      Pages 151-160

    18. Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML

      • Ollivier Legrand, Ghislaine Simonin, Jean-Yves Perrot, Robert Zittoun, Jean-Pierre Marie
      Pages 161-175

    19. Absolute Levels of MDR-1, MRP, and BCL-2 MRNA and Tumor Remission in Acute Leukemia

      • T. Köhler, S. Leiblein, S. Borchert, J. Eller, A.-K. Rost, D. Laßner et al.
      Pages 177-185
Back to top

Keywords

About this book

Cellular drug resistance is a major limitation to the success of chemotherapy of leu­ kemia and lymphoma. The importance of this has now been recognized by both clinicians and scientists. It is of utmost importance to bridge the gap between laboratory and clinic in this field of research. This is the main purpose of the series of International Symposia on Drug Resistance in Leukemia and Lymphoma. These are held every three years in Am­ sterdam, The Netherlands, since 1992. This book contains the proceedings of the third of these meetings, organised in 1998. The book covers all important aspects of drug resistance in leukemia and lymphoma, both in the form of extensive reviews as in manuscripts describing original data. General mechanisms of resistance are discussed, including the drug resistance related proteins p­ glycoprotein, MRP (multi-drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases. Moreover, more drug type-specific mechanisms of resistance are a topic, such as for glucocorticoids and antifolates. Much in­ formation is provided on apoptosis and its regulators, and on the results of cell culture drug resistance assays. Several papers focus on the modulation or circumvention of drug resistance.

Editors and Affiliations

  • University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    G. J. L. Kaspers, R. Pieters, A. J. P. Veerman

Bibliographic Information

  • Book Title: Drug Resistance in Leukemia and Lymphoma III

  • Editors: G. J. L. Kaspers, R. Pieters, A. J. P. Veerman

  • Series Title: Advances in Experimental Medicine and Biology

  • DOI: https://doi.org/10.1007/978-1-4615-4811-9

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 1999

  • Hardcover ISBN: 978-0-306-46055-5Published: 30 September 1999

  • Softcover ISBN: 978-1-4613-7180-9Published: 05 November 2012

  • eBook ISBN: 978-1-4615-4811-9Published: 06 December 2012

  • Series ISSN: 0065-2598

  • Series E-ISSN: 2214-8019

  • Edition Number: 1

  • Number of Pages: XIV, 638

  • Topics: Oncology, Internal Medicine, Hematology

Publish with us

Policies and ethics

Back to top

Search

Navigation